Terminated PHASE3 INTERVENTIONAL 2-arm NCT00699283

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.

Sponsor: UCB Pharma

Conditions Epilepsy

Interventions Brivaracetam

Updated 12 times since 2017 Last updated: Jun 13, 2018 Started: Aug 31, 2008 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

An interim analysis revealed the study was unlikely to attain a positive outcome for the efficacy analysis. No safety concerns were detected

Other terminated trials from UCB Pharma

See all terminations from UCB Pharma

Other Epilepsy trials with similar outcome

Browse all Epilepsy trials

A PHASE3 clinical study on Epilepsy, this trial is terminated or withdrawn. The trial is conducted by UCB Pharma and has accumulated 12 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 7 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Aug 2018 — Nov 2020 [monthly]

Terminated PHASE3
Jun 2018 — Aug 2018 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Atlanta, United States , Austin, United States , Barcelona, Spain , Bedford, United States , Bergamo, Italy , Berlin, Germany , Bernau, Germany , Bethlehem, United States , Bielefeld, Germany and 58 more locations